Previous studies have shown that anti-PRL agents, such as BCR, a dopamine D2 receptor agonist, not only improved cardiac function by reducing the plasma 16 K PRL levels2 but also suppressed cardiac hypertrophy by suppressing the plasma aldosterone and 23 K PRL levels during the lactation term16. This evidence concerns the gene PRL and cardiac hypertrophy.